Marcyrl Pharmaceutical Industries’ Post

📢 Exciting News! Our latest review article, "Managing Anemia with Desidustat in a Hyporesponsiveness to Erythropoietin-Stimulating Agents among CKD Patients," is now published in the International Journal of Pharmacy & Pharmaceutical Research! Explore how Desidustat offers a promising therapeutic option for CKD patients struggling with ESA resistance. #Research #CKD #Anemia #Desidustat #Pharmacy #PharmaceuticalResearch #HealthcareInnovation

𝐌𝐞𝐝𝐒𝐚𝐟𝐞𝐭𝐲𝐖𝐞𝐞𝐤 𝟒 - 𝟏𝟎 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 - 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐧𝐠 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬   As per the Global Patient Safety Report 2024, published by the WHO, the occurrence of adverse events, resulting from unsafe care, is likely to be one of the 10 leading causes of death and disability worldwide.   Indeed, a significant number of adverse drug reactions (ADRs) could be avoided. Being aware of relevant factors that lead to preventable side effects and implementing strategies for mitigating these risks - potentially supported by artificial intelligence (AI) - is key to improving patient safety.   Hence, take this article by IFAPP Pharmacovigilance Working Group as a warm-up for the UMC’s global awareness week.     #MedSafetyWeek #PharmaceuticalMedicine #Pharmacovigilance #IFAPP

Six “Antimicrobial Resistance (AMR) Roadmaps”, one for each of the World Health Organization regions, that define and prioritise major milestones towards mitigating AMR for the period 2024 to 2028, are published by FIP today. The roadmaps were developed by FIP in collaboration with its regional pharmaceutical forums and, for the European Region, with FIP member organisations in Europe as there is no FIP regional pharmaceutical forum in the European region. The new roadmaps have been developed to follow roadmaps for 2020-2024. The new publication also presents various activities against AMR that have been undertaken in countries of each region. Access the roadmaps here www.fip.org/file/6112

Adalvo has submitted its 𝐃𝐂𝐏 𝐟𝐢𝐥𝐢𝐧𝐠 𝐟𝐨𝐫 𝐓𝐞𝐝𝐮𝐠𝐥𝐮𝐭𝐢𝐝𝐞 on Day-1 following the 𝐞𝐱𝐩𝐢𝐫𝐲 𝐨𝐟 𝐃𝐚𝐭𝐚 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐢𝐭𝐲. This submission presents a 𝐟𝐢𝐫𝐬𝐭-𝐭𝐨-𝐦𝐚𝐫𝐤𝐞𝐭 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 for Adalvo, underscoring our commitment to addressing unmet medical needs in the rare disease segment. With 𝐧𝐨 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐟𝐨𝐫 𝐒𝐁𝐒, the wider availability of Teduglutide is highly anticipated. This strategic filing reflects Adalvo’s focus on providing high-value, differentiated products to the market 𝐩𝐫𝐨𝐦𝐩𝐭𝐥𝐲 𝐚𝐧𝐝 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭𝐥𝐲. Click here to find out more - https://lnkd.in/exNPt6wC #Adalvo #AlwaysOnTarget #Teduglutide #DCPFiling

Six “Antimicrobial Resistance (AMR) Roadmaps”, one for each of the World Health Organization regions, that define and prioritise major milestones towards mitigating AMR for the period 2024 to 2028, are published by FIP today. The roadmaps were developed by FIP in collaboration with its regional pharmaceutical forums and, for the European Region, with FIP member organisations in Europe as there is no FIP regional pharmaceutical forum in the European region. The new roadmaps have been developed to follow roadmaps for 2020-2024. The new publication also presents various activities against AMR that have been undertaken in countries of each region. Access the roadmaps here👉 www.fip.org/file/6112

FDA approved an Investigational New Drug (IND) application for Naronapride to treat PPI-non-responsive symptomatic gastroesophageal reflux disease (GERD) . Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic, which works by modulating two validated targets on the luminal surface of the intestinal wall, 5-HT4 receptor agonism and D2 receptor antagonism, with a well-differentiated pharmaceutical, pharmacokinetics, safety, and efficacy profile from other 5-HT4 agonists. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/ghSeX_Ka #Naronapride #ATI-7505 #gastroesophagealrefluxdisease #GERD #5-HT4receptor #buildingblocks

Significant Progress in the Pharmaceutical Sector: FDA-Approved First Therapy for MASH! ✌ On 14th March 2024, FDA approved Madrigal Pharmaceuticals' Rezdiffra, the first treatment for steatohepatitis associated with metabolic dysfunction (MASH), signaling the end of the protracted search for a feasible remedy. Rezdiffra provides new hope for patients who were previously without targeted treatment options by treating patients with MASH, which is characterized by moderate to severe liver scarring. Rezdiffra approval establishes a ground-breaking precedent for future treatments in a field that is estimated to affect approximately 5% of adult Americans. Recently, potential competitors to Madrigal's (MDGL) treatment have also shown improvement. The news last week that Akero Therapeutics Inc.'s (AKRO) experimental treatment for MASH, efruxifermin, was showing encouraging results from a mid-stage trial caused its stock price to soar. Additionally, MASH patients will now be able to participate in 89bio Inc.'s (ET)(N)(B) phase 3 trial for Pegozafermin, an investigational medication. Rezdiffra is expected to have peak global sales of $5.5 billion, so this approval not only fills a significant gap in the MASH treatment market but also represents a sizable opportunity. #MadrigalPharmaceuticals #fdaapproval #Rezdiffra #mash #competitiveintelligence

Six “Antimicrobial Resistance (AMR) Roadmaps”, one for each of the World Health Organization regions, that define and prioritise major milestones towards mitigating AMR for the period 2024 to 2028, are published by FIP today. The roadmaps were developed by FIP in collaboration with its regional pharmaceutical forums and, for the European Region, with FIP member organisations in Europe as there is no FIP regional pharmaceutical forum in the European region. The new roadmaps have been developed to follow roadmaps for 2020-2024. The new publication also presents various activities against AMR that have been undertaken in countries of each region. Access the roadmaps here www.fip.org/file/6112

This reflect a crucial aspect of pharmaceutical pricing and access to medicine. In any society, the affordability of medicine is intricately linked to the income levels of its citizens, particularly non-skilled workers who often face financial constraints. Price controls play a vital role in ensuring that essential and nonessential medications remain accessible to all, regardless of economic status. Without proper regulation, the pharmaceutical industry in a capitalist society could prioritize profit over public health, leading to exorbitant prices that effectively exclude the most vulnerable populations from accessing life-saving treatments. As you rightly pointed out, fatal diseases do not discriminate based on wealth or social status. Removing price controls without adequate safeguards could exacerbate inequalities in accessing medicines, leaving disadvantaged patients at the mercy of market forces. It's imperative for regulatory bodies and policymakers to prioritize the protection of poor patients by implementing measures that promote affordability and equitable access to essential medications. Otherwise, the consequences could be dire, with lives hanging in the balance due to the inability to afford vital treatments.

With compliments of the IFAPP - International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine - Communication Working Group, you can read here the nineth edition of IFAPP TODAY of 2024! Great contributions from and about: * Celebration of MedSafetyWeek: Preventing Side Effects * MEAPP 2nd Annual Conference: Pharmaceutical Medicine Domiciliation in the Middle East * Review of and Update on Mpox * Why I Chose a Career in Pharmaceutical Medicine: My Story * Navigating Your First Year: Insights and Strategies for Newcomers in Clinical Trials * ICPM 2025 #pharmaceuticalmedicine #clintrials #clinresearch #RWD #HealthCare #IFAPP #EUCTR #AI #pharmacology #ICPM2025 #regulation